Shattuck Labs, Inc. (STTK)
NMS – Real vaqt narxi. Valyuta: USD
6.62
-0.40 (-5.70%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Find any stock by ticker or company name

NMS – Real vaqt narxi. Valyuta: USD
6.62
-0.40 (-5.70%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Shattuck Labs, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Qo'shma Shtatlarda yallig'lanish va immunitet vositasidagi kasalliklarni davolash uchun antitelalarni ishlab chiqish bilan shug'ullanadi. Kompaniya o'simta nekrozi omili 1A ligandini davolash uchun I faza klinik sinovidan o'tayotgan o'lim retseptorlari 3 blokirovka qiluvchi monoklonal antitelani SL-325; va SL-325 ning yarim umri uzaytirilgan versiyasi bo'lgan SL-425ni ishlab chiqadi, bu IND-tayyorlanish xronik yaxshi laboratoriya amaliyotlari toksikologiya tadqiqotida. Kompaniya, shuningdek, yallig'lanishli ichak kasalligi yoki boshqa immunitet vositasidagi ko'rsatmalarga ega bemorlarni davolash uchun turli xil preklinik DR3 asosidagi bispesifik antitelalarni ishlab chiqish; va onkologiyaga yo'naltirilgan dastur bo'lgan TRIM7 bilan ham shug'ullanadi. Kompaniya 2016-yilda ro'yxatga olingan va shtab-kvartirasi Ostin, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer |
| Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer |
| Dr. Stephen Stout J.D., Ph.D. | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer |
| Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, CEO & Director |
| Dr. Thomas Lampkin Pharm.D. | Senior Vice President of Regulatory Affairs |
| Mr. Andrew R. Neill M.B.A. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | sttk-20260507.htm |
| 2026-04-08 | DEFA14A | d143192ddefa14a.htm |
| 2026-03-05 | 8-K | sttk-20260305.htm |
| 2026-03-05 | 10-K | sttk-20251231.htm |
| 2026-02-05 | 8-K | d76999d8k.htm |
| 2026-01-22 | 8-K | d59331d8k.htm |
| 2026-01-13 | S-3 | d81498ds3.htm |
| 2025-11-06 | 8-K/A | sttk-20251106.htm |
| 2025-09-24 | CORRESP | filename1.htm |
| 2025-09-18 | S-3 | d859067ds3.htm |
| Chief Financial Officer |
| Mr. Brad Huckabee | Vice President of Accounting & SEC reporting |
| Mr. Suresh de Silva Ph.D. | Chief Scientific Officer |
| Ms. Casi DeYoung | Chief Business Officer |
| Ms. Kelli Collin M.S. | Senior Vice President of Quality |